Phase I and II Study of Exisulind in Combination With Capecitabine in Patients With Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase I and II Study of Exisulind in Combination With Capecitabine in Patients With Metastatic Breast Cancer

54

Citations

15

References

2003

Year

Lajos Pusztai, Jim Hou Zhen, Banu Arun, Edgardo Rivera, Clark M. Whitehead, William J. Thompson, Kimberly M. Nealy, Amy Gibbs, W. Fraser Symmans, Francisco J. Esteva,

Journal of Clinical Oncology

Abstract

Exisulind (125 mg orally bid) in combination with capecitabine is well tolerated and the combination has anticancer activity similar to that of capecitabine alone in heavily pretreated patients with MBC.

References

	Year	Citations

Page 1